Cargando…

The role of VEGF, PDGF and IL-6 on diabetic foot ulcer after Platelet Rich Fibrin + hyaluronic therapy

BACKGROUND: Current standard management of diabetic foot ulcers (DFUs) consists of surgical debridement followed by soak NaCl 0.9% gauzes tight infection and glycaemic control. Nowadays the use of advanced platelet-rich fibrin (A-PRF) has emerged as an adjunctive method for treating DFUs. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Kartika, Ronald W., Alwi, Idrus, Suyatna, Franciscus D., Yunir, Em, Waspadji, Sarwono, Immanuel, Suzzana, Silalahi, Todung, Sungkar, Saleha, Rachmat, Jusuf, Reksodiputro, Mirta Hediyati, Bardosono, Saptawati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455691/
https://www.ncbi.nlm.nih.gov/pubmed/34585000
http://dx.doi.org/10.1016/j.heliyon.2021.e07934
_version_ 1784570724866850816
author Kartika, Ronald W.
Alwi, Idrus
Suyatna, Franciscus D.
Yunir, Em
Waspadji, Sarwono
Immanuel, Suzzana
Silalahi, Todung
Sungkar, Saleha
Rachmat, Jusuf
Reksodiputro, Mirta Hediyati
Bardosono, Saptawati
author_facet Kartika, Ronald W.
Alwi, Idrus
Suyatna, Franciscus D.
Yunir, Em
Waspadji, Sarwono
Immanuel, Suzzana
Silalahi, Todung
Sungkar, Saleha
Rachmat, Jusuf
Reksodiputro, Mirta Hediyati
Bardosono, Saptawati
author_sort Kartika, Ronald W.
collection PubMed
description BACKGROUND: Current standard management of diabetic foot ulcers (DFUs) consists of surgical debridement followed by soak NaCl 0.9% gauzes tight infection and glycaemic control. Nowadays the use of advanced platelet-rich fibrin (A-PRF) has emerged as an adjunctive method for treating DFUs. This study was conducted to demonstrate the ability of combine A-PRF + HA as a complementary therapy in DFUs healing related with angiogenesis,inflammation and granulation index process. METHODS: This open label randomized controlled trial was conducted in Koja District Hospital and Gatot Soebroto Hospital Jakarta, Indonesia on July 2019–April 2020. DFUs patients with wound duration of three months, Wagner-2, with size of ulcer less than 40 cm(2) were included in the study. The number of subjects was calculated based on the rule of thumb and allocated randomly into three groups, namely topical A-PRF + HA, A-PRF and Sodium Chloride 0.9% as a control, for each of 10 subjects. A-PRF made by 10 mL venous blood, centrifuge 200 G in 10 min, meanwhile A-PRF + HA though mix both them with vertex machine around 5 min. Biomarker such as VEGF, PDGF and IL-6 examined from DFU taken by cotton swab and analysis using ELISA. Granulation Index was measured using ImageJ. Biomarkers and granulation index were evaluated on day 0, 3, 7 and 14. Data were analysed using SPSS version 20 with Anova and Kruskal Wallis test to compare the angiogenesis and inflammation effect between the three groups. RESULT: In topical dressing A-PRF + HA, there is an increase in delta VEGF on day-3 (43.1 pg/mg protein) and day-7 (275,8 pg/mg protein) compared to A-PRF on day-3 (1.8 pg/mg protein) and day-7 (104.7 pg/mg protein), also NaCl (control) on day-3 (-4.9 pg/mg protein) and day-7 (28.3 pg/mg protein). So that the delta VEGF of A-PRF + HA group increase significantly compared with others on day-3 (p = 0.003) and day- 7 (p < 0.001). Meanwhile A-PRF + AH group, there is also a decrease in delta IL-6 after therapy on day-3 (-10.9 pg/mg protein) and day-7 (-18.3 pg/mg protein) compared to A-PRF in delta IL-6 on day- 3 (-3.7 pg/mg protein) and on day-7 (-7.8 pg/mg protein). In NaCl (control) group there is a increase delta IL-6 on day-3 (4.3 pg/mg protein) and on day-7 (35.5 pg/mg protein). So that the delta IL-6 of A-PRF + HA group decrease significantly compared with others only on day- 7 (p = 0.015). In PDGF le level analysis, A-PRF + HA group increase significantly (p = 0.012) only in day -7 compare with other group (5.5 pg/mg protein). CONCLUSION: The study shows the superior role of combined A-PRF + HA in the treatment DFU though increase angiogenesis and decrease inflammation pathway. The advantage of using A-PRF + HA is that it accelerates wound healing by increasing granulation tissue compared to A-PRF alone.
format Online
Article
Text
id pubmed-8455691
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84556912021-09-27 The role of VEGF, PDGF and IL-6 on diabetic foot ulcer after Platelet Rich Fibrin + hyaluronic therapy Kartika, Ronald W. Alwi, Idrus Suyatna, Franciscus D. Yunir, Em Waspadji, Sarwono Immanuel, Suzzana Silalahi, Todung Sungkar, Saleha Rachmat, Jusuf Reksodiputro, Mirta Hediyati Bardosono, Saptawati Heliyon Research Article BACKGROUND: Current standard management of diabetic foot ulcers (DFUs) consists of surgical debridement followed by soak NaCl 0.9% gauzes tight infection and glycaemic control. Nowadays the use of advanced platelet-rich fibrin (A-PRF) has emerged as an adjunctive method for treating DFUs. This study was conducted to demonstrate the ability of combine A-PRF + HA as a complementary therapy in DFUs healing related with angiogenesis,inflammation and granulation index process. METHODS: This open label randomized controlled trial was conducted in Koja District Hospital and Gatot Soebroto Hospital Jakarta, Indonesia on July 2019–April 2020. DFUs patients with wound duration of three months, Wagner-2, with size of ulcer less than 40 cm(2) were included in the study. The number of subjects was calculated based on the rule of thumb and allocated randomly into three groups, namely topical A-PRF + HA, A-PRF and Sodium Chloride 0.9% as a control, for each of 10 subjects. A-PRF made by 10 mL venous blood, centrifuge 200 G in 10 min, meanwhile A-PRF + HA though mix both them with vertex machine around 5 min. Biomarker such as VEGF, PDGF and IL-6 examined from DFU taken by cotton swab and analysis using ELISA. Granulation Index was measured using ImageJ. Biomarkers and granulation index were evaluated on day 0, 3, 7 and 14. Data were analysed using SPSS version 20 with Anova and Kruskal Wallis test to compare the angiogenesis and inflammation effect between the three groups. RESULT: In topical dressing A-PRF + HA, there is an increase in delta VEGF on day-3 (43.1 pg/mg protein) and day-7 (275,8 pg/mg protein) compared to A-PRF on day-3 (1.8 pg/mg protein) and day-7 (104.7 pg/mg protein), also NaCl (control) on day-3 (-4.9 pg/mg protein) and day-7 (28.3 pg/mg protein). So that the delta VEGF of A-PRF + HA group increase significantly compared with others on day-3 (p = 0.003) and day- 7 (p < 0.001). Meanwhile A-PRF + AH group, there is also a decrease in delta IL-6 after therapy on day-3 (-10.9 pg/mg protein) and day-7 (-18.3 pg/mg protein) compared to A-PRF in delta IL-6 on day- 3 (-3.7 pg/mg protein) and on day-7 (-7.8 pg/mg protein). In NaCl (control) group there is a increase delta IL-6 on day-3 (4.3 pg/mg protein) and on day-7 (35.5 pg/mg protein). So that the delta IL-6 of A-PRF + HA group decrease significantly compared with others only on day- 7 (p = 0.015). In PDGF le level analysis, A-PRF + HA group increase significantly (p = 0.012) only in day -7 compare with other group (5.5 pg/mg protein). CONCLUSION: The study shows the superior role of combined A-PRF + HA in the treatment DFU though increase angiogenesis and decrease inflammation pathway. The advantage of using A-PRF + HA is that it accelerates wound healing by increasing granulation tissue compared to A-PRF alone. Elsevier 2021-09-07 /pmc/articles/PMC8455691/ /pubmed/34585000 http://dx.doi.org/10.1016/j.heliyon.2021.e07934 Text en © 2021 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Kartika, Ronald W.
Alwi, Idrus
Suyatna, Franciscus D.
Yunir, Em
Waspadji, Sarwono
Immanuel, Suzzana
Silalahi, Todung
Sungkar, Saleha
Rachmat, Jusuf
Reksodiputro, Mirta Hediyati
Bardosono, Saptawati
The role of VEGF, PDGF and IL-6 on diabetic foot ulcer after Platelet Rich Fibrin + hyaluronic therapy
title The role of VEGF, PDGF and IL-6 on diabetic foot ulcer after Platelet Rich Fibrin + hyaluronic therapy
title_full The role of VEGF, PDGF and IL-6 on diabetic foot ulcer after Platelet Rich Fibrin + hyaluronic therapy
title_fullStr The role of VEGF, PDGF and IL-6 on diabetic foot ulcer after Platelet Rich Fibrin + hyaluronic therapy
title_full_unstemmed The role of VEGF, PDGF and IL-6 on diabetic foot ulcer after Platelet Rich Fibrin + hyaluronic therapy
title_short The role of VEGF, PDGF and IL-6 on diabetic foot ulcer after Platelet Rich Fibrin + hyaluronic therapy
title_sort role of vegf, pdgf and il-6 on diabetic foot ulcer after platelet rich fibrin + hyaluronic therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455691/
https://www.ncbi.nlm.nih.gov/pubmed/34585000
http://dx.doi.org/10.1016/j.heliyon.2021.e07934
work_keys_str_mv AT kartikaronaldw theroleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT alwiidrus theroleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT suyatnafranciscusd theroleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT yunirem theroleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT waspadjisarwono theroleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT immanuelsuzzana theroleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT silalahitodung theroleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT sungkarsaleha theroleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT rachmatjusuf theroleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT reksodiputromirtahediyati theroleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT bardosonosaptawati theroleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT kartikaronaldw roleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT alwiidrus roleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT suyatnafranciscusd roleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT yunirem roleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT waspadjisarwono roleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT immanuelsuzzana roleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT silalahitodung roleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT sungkarsaleha roleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT rachmatjusuf roleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT reksodiputromirtahediyati roleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy
AT bardosonosaptawati roleofvegfpdgfandil6ondiabeticfootulcerafterplateletrichfibrinhyaluronictherapy